全文获取类型
收费全文 | 2941篇 |
免费 | 155篇 |
国内免费 | 19篇 |
专业分类
耳鼻咽喉 | 11篇 |
儿科学 | 39篇 |
妇产科学 | 30篇 |
基础医学 | 385篇 |
口腔科学 | 71篇 |
临床医学 | 254篇 |
内科学 | 524篇 |
皮肤病学 | 40篇 |
神经病学 | 197篇 |
特种医学 | 481篇 |
外科学 | 650篇 |
综合类 | 8篇 |
预防医学 | 66篇 |
眼科学 | 41篇 |
药学 | 94篇 |
中国医学 | 1篇 |
肿瘤学 | 223篇 |
出版年
2024年 | 8篇 |
2023年 | 62篇 |
2022年 | 104篇 |
2021年 | 168篇 |
2020年 | 81篇 |
2019年 | 103篇 |
2018年 | 139篇 |
2017年 | 101篇 |
2016年 | 122篇 |
2015年 | 115篇 |
2014年 | 144篇 |
2013年 | 168篇 |
2012年 | 257篇 |
2011年 | 241篇 |
2010年 | 130篇 |
2009年 | 106篇 |
2008年 | 161篇 |
2007年 | 168篇 |
2006年 | 124篇 |
2005年 | 102篇 |
2004年 | 77篇 |
2003年 | 77篇 |
2002年 | 95篇 |
2001年 | 18篇 |
2000年 | 11篇 |
1999年 | 10篇 |
1998年 | 15篇 |
1997年 | 8篇 |
1996年 | 13篇 |
1995年 | 8篇 |
1994年 | 5篇 |
1993年 | 5篇 |
1992年 | 5篇 |
1991年 | 6篇 |
1990年 | 5篇 |
1988年 | 4篇 |
1982年 | 4篇 |
1980年 | 6篇 |
1979年 | 4篇 |
1978年 | 4篇 |
1977年 | 5篇 |
1931年 | 5篇 |
1928年 | 6篇 |
1927年 | 4篇 |
1923年 | 4篇 |
1910年 | 3篇 |
1905年 | 3篇 |
1902年 | 3篇 |
1896年 | 3篇 |
1893年 | 5篇 |
排序方式: 共有3115条查询结果,搜索用时 0 毫秒
991.
Eder M Waldenfels FV Swobodnik A Klöppel M Pape AK Schuster T Raith S Kitzler E Papadopulos NA Machens HG Kovacs L 《Breast (Edinburgh, Scotland)》2012,21(2):152-158
This study develops an objective breast symmetry evaluation using 3-D surface imaging (Konica-Minolta V910® scanner) by superimposing the mirrored left breast over the right and objectively determining the mean 3-D contour difference between the 2 breast surfaces. 3 observers analyzed the evaluation protocol precision using 2 dummy models (n = 60), 10 test subjects (n = 300), clinically tested it on 30 patients (n = 900) and compared it to established 2-D measurements on 23 breast reconstructive patients using the BCCT.core software (n = 690). Mean 3-D evaluation precision, expressed as the coefficient of variation (VC), was 3.54 ± 0.18 for all human subjects without significant intra- and inter-observer differences (p > 0.05). The 3-D breast symmetry evaluation is observer independent, significantly more precise (p < 0.001) than the BCCT.core software (VC = 6.92 ± 0.88) and may play a part in an objective surgical outcome analysis after incorporation into clinical practice. 相似文献
992.
993.
Bockmeyer CL Kern DS Forstmeier V Lovric S Modde F Agustian PA Steffens S Birschmann I Traeder J D?mmrich ME Schwarz A Kreipe HH Br?cker V Becker JU 《Nephrology, dialysis, transplantation》2012,27(9):3493-3501
Background Benign nephrosclerosis (bN) is the most prevalent form of hypertensive damage in kidney biopsies. It is defined by early hyalinosis and later fibrosis of renal arterioles. Despite its high prevalence, very little is known about the contribution of arteriolar vascular smooth muscle cells (VSMCs) to bN. We examined classical and novel candidate markers of the normal contractile and the pro-fibrotic secretory phenotype of VSMCs in arterioles in bN. Methods Sixty-three renal tissue specimens with bN and eight control specimens were examined by immunohistochemistry for the contractile markers caldesmon, alpha-smooth muscle actin (alpha-SMA), JunB, smoothelin and the secretory marker S100A4 and by double stains for caldesmon or smoothelin with S100A4. Results Smoothelin immunostaining showed an inverse correlation with hyalinosis and fibrosis scores, while S100A4 correlated with fibrosis scores only. Neither caldesmon, alpha-SMA nor JunB correlated with hyalinosis or fibrosis scores. Cells in the arteriolar wall were exclusively positive either for caldesmon/smoothelin or S100A4. Conclusions This is the first systematic analysis of VSMC differentiation in bN. The results suggest that smoothelin is the most sensitive marker for the contractile phenotype and that S100A4 could be a novel marker for the secretory phenotype in vivo. The other markers did not seem to differentiate these phenotypes in bN. Thus, VSMC phenotype markers should be defined in the context of the vessel segment and disease under examination. S100A4 could not only be a marker of pro-fibrotic secretory VSMCs in bN but also an important mediator of arteriolar fibrosis. 相似文献
994.
995.
996.
M Zacherl N Kastner M Glehr S Scheipl G Schwantzer H Koch A Leithner R Windhager 《Orthopedics》2012,35(8):e1214-e1220
Soft tissue sarcomas are a group of rare mesenchymal neoplasms comprising 0.8% of all malignant tumors. Workup should include medical history, physical examination, magnetic resonance imaging, biopsy, and thoracoabdominal computed tomography scan, in that order. Centralized multimodality treatment in a cross-disciplinary setting is mandatory. Treatment not according to current clinical practice guidelines is a common problem before referral to a specialized institution. The purpose of this 10-year, single-institution review was to investigate the influence of curative surgery on outcome, with a special emphasis on surgery before referral.A cohort of 266 patients who underwent curative surgery for soft tissue sarcoma between 1998 and 2008 was analyzed. One hundred thirty-one (49%) patients underwent surgery contrary to current clinical guidelines before referral, most (73%) at primary care units. One hundred thirteen (86%) of these patients underwent surgery without previous biopsy with a higher rate of intralesional margins (P<.001), a smaller mean diameter of primary lesion (P<.001), a higher rate of subcutaneous situs (P<.001), a lower mean American Joint Committee on Cancer score (P=.008), a higher rate of additional plastic surgery after re-resection (eg, flap surgery) (P<.001), and a longer period before referral (P<.001). No influence on survival, local recurrence, or metastasis existed.Prereferral surgery necessitating re-resection has no influence on survival but leads to an unfavorable clinical course. More effort should be made to improve awareness and referral modalities for general practitioners and physicians at community hospitals. 相似文献
997.
998.
Leucht Stefan Huhn Maximilian Davis John M. 《European archives of psychiatry and clinical neuroscience》2021,271(8):1411-1413
European Archives of Psychiatry and Clinical Neuroscience - 相似文献
999.
Lennart Wedekind Jan-Frederik Güth Josef Schweiger Maximilian Kollmuss Franz-Xaver Reichl Daniel Edelhoff Christof Högg 《Dental materials》2021,37(4):701-710
ObjectiveThe elution of unpolymerized (co-)monomers and additives from methacrylic resin-based materials like polymethyl methacrylate (PMMA) can cause adverse side effects, such as mutagenicity, teratogenicity, genotoxicity, cytotoxicity and estrogenic activity.The aim of this study was to quantify the release and the cytotoxicity of residual (co-)monomers and additives from PMMA-based splint materials under consideration of real splint sizes. Three different materials used for additive (3D printing), subtractive (milling) and conventional (powder and liquid) manufacturing were examined.MethodsThe splint materials SHERAprint-ortho plus (additive), SHERAeco-disc PM20 (subtractive) and SHERAORTHOMER (conventional) were analysed. 16 (n = 4) sample discs of each material (6 mm diameter and 2 mm height) were polished on the circular and one cross-section area and then eluted in both distilled water and methanol. The discs were incubated at 37 °C for 24 h or 72 h and subsequently analysed by gas chromatography/mass spectrometry (GC/MS) for specifying and quantifying released compounds. XTT-based cell viability assays with human gingival fibroblasts (HGFs) were performed for Tetrahydrofurfuryl methacrylate (THFMA), 1,4-Butylene glycol dimethacrylate (BDDMA) and Tripropylenglycol diacrylate (TPGDA). In order to project the disc size to actual splint sizes in a worst-case scenario, lower and upper jaw occlusal splints were designed and volumes and surfaces were measured.ResultsFor SHERAeco-disc PM20 and for SHERAORTHOMER no elution was determined in water. SHERAprint-ortho plus eluted the highest THFMA concentration of 7.47 μmol/l ±2,77 μmol/l after 72 h in water. Six (co-)monomers and five additives were detected in the methanol eluates of all three materials tested. The XTT-based cell viability assays resulted in a EC50 of 3006 ± 408 μmol/l for THFMA, 2569.5 ± 308 μmol/l for BDDMA and 596.7 ± 88 μmol/l for TPGDA.SignificanceWith the solvent methanol, released components from the investigated splint materials exceeded cytotoxic concentrations in HGFs calculated for a worst-case scenario in splint size. In the water eluates only the methacrylate THFMA could be determined from SHERAprint-ortho plus in concentrations below cytotoxic levels in HGFs. 相似文献
1000.
Moritz J. Strowitzki Stefan Dold Maximilian von Heesen Christina Körbel Claudia Scheuer Mohammed R. Moussavian Martin K. Schilling Otto Kollmar Michael D. Menger 《Clinical & experimental metastasis》2014,31(7):795-803
Liver failure after extended hepatectomy represents a major challenge in the surgery of hepatic colorectal metastasis. A previous study has indicated that inhibition of phosphodiesterase type 3 (PDE 3) stimulates liver regeneration. However, little is known whether PDE 3 inhibitors, such as cilostazol, also stimulate the growth of remnant metastases. Therefore, we herein studied the effect of cilostazol on engraftment, vascularization and growth of colorectal liver metastasis after major hepatectomy. WAG-rats underwent either major hepatectomy or sham operation. Metastases were induced by subcapsular implantation of 5 × 105 CC531-colorectal cancer cells. Animals were daily treated with cilostazol (5 mg/kg body weight) or glucose solution. Tumor growth was measured by high-resolution ultrasound at days 7 and 14. Tumor vascularization and tumor cell proliferation were determined by immunohistochemistry and western blotting. High-resolution ultrasound analysis in hepatectomized and non-hepatectomized animals showed that cilostazol does not stimulate tumor growth. Accordingly, the number of PCNA-positive tumor cells did not differ between cilostazol-treated animals and sham-treated controls. Interestingly, cilostazol reduced tumor vascularization in both hepatectomized and non-hepatectomized animals. This was indicated by a significantly lower number of platelet-endothelial cell adhesion molecule (PECAM-1)-positive cells in tumors of cilostazol-treated animals compared to sham-treated controls. The PDE 3 inhibitor cilostazol does not stimulate the growth of colorectal metastases during liver regeneration after major hepatectomy. 相似文献